BioNTech (BNTX) is still one of the most explosive vaccine stocks on makret.
Since bottoming out in April 2020, it has run from a low of $37 to $87.77, and could head higher. For one, the US FDA just “fast tracked” a vaccine it’s developing with Pfizer.
According to BioNTech, two of the company’s four investigational candidates from its BNT162 mRNA-based program being developed to help protect against the virus were “fast tracked.”
Going forward, Pfizer and BioNTech expect to start the next phase of the vaccine trial later this month with 30,000 subjects. If successful, the two expect to have 100 million doses of the vaccine by the close of 2020, and more than 1.2 billion by the end of 2021.
Two, BNTX is running on news the UK signed a deal to secure 90 million doses of two potential vaccines from BioNTech and Pfizer.